Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when GTBP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsGT Biopharma commits up to $3.8M to University of Minnesota phase 1 trial of GTB-5550 in solid tumors
Filed April 7, 2026 · Period ending April 3, 2026 · ~1 min read
Key Changes
-
high
Company entered clinical trial agreement with University of Minnesota for phase 1a/1b study of GTB-5550, a tri-specific nanobody therapy, in advanced solid tumor patients who failed prior treatment
Item 1.01 verify on EDGAR → -
high
GT Biopharma will fund up to $3.8 million over three years for the study, representing a material cash commitment that will impact the company's burn rate and financial runway
Item 1.01 verify on EDGAR → -
medium
University of Minnesota will sponsor the IND application (IND 169118) and serve as sponsor investigator, shifting some regulatory responsibility to the academic institution
Item 1.01 verify on EDGAR → -
medium
Either party can terminate the agreement with 30 days' notice; University can terminate immediately for safety reasons, creating potential discontinuation risk for invested capital
Item 1.01 verify on EDGAR →
Summary
GT Biopharma has launched a phase 1 clinical trial for GTB-5550, its camelid nanobody therapy targeting B7-H3, through a partnership with the University of Minnesota. The company will invest up to $3.8 million over three years to fund the study, which will enroll patients with advanced solid tumors who have exhausted other treatment options.
This represents a significant financial commitment for the small biotech company. For retail investors, this trial marks a key milestone in advancing GTB-5550 through clinical development. The investigator-initiated structure means the University will handle IND sponsorship and study management, potentially reducing GT Biopharma's operational burden while still requiring substantial funding.
Success in this early-stage trial could validate the platform and attract partnership interest, while failure would represent both a scientific and financial setback. Watch for initial safety and dosing data from the phase 1a portion of the trial, likely within 12-18 months. Also monitor the company's cash position in upcoming quarterly reports to assess whether additional financing will be needed to complete the full three-year study period.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Agreement may be terminated by the Company or the University at any time upon thirty days’ written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty days.
Either party can terminate the agreement with 30 days' notice, and the University can terminate immediately for safety reasons. This provides flexibility but also means the trial could be discontinued, potentially impacting the company's development timeline and invested capital.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Investigator Initiated Clinical Trial Agreement, dated as of April 3, 2026, by and between GT Biopharma, Inc. and the Regents of the University of Minnesota.
GT Biopharma has entered into an investigator-initiated clinical trial agreement with the University of Minnesota. This type of agreement typically means the university will conduct a clinical study of one of the company's drug candidates, which could advance the company's pipeline and provide clinical data. The specific terms and schedules have been omitted from the public filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify